SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 36877973.
- Also identified by DOI 10.7326/J23-0002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. <b>Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.</b> Lancet. 2022;400:1788-801. 36351458.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors